Each ml contains:
Active Substance: Olopatadine Hydrochloride USP equivalent to Olopatadine 7 mg.
Preservative: Purite 0.075 mg.
Patadin Max is a sterile ophthalmic solution containing Olopatadine Hydrochloride, a relatively selective H₁ receptor antagonist and a mast cell stabilizer, for topical administration to the eyes.
Clinical Pharmacology:
Olopatadine is a mast cell stabilizer and a histamine H₁ antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. Olopatadine inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cell. It has no effect on alpha-adrenergic, dopamine and muscarinic type 1 and type 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.
Patadin Max is a sterile eye drops is indicated for the treatment of signs and symptoms (itchy, watery, swollen eyes and/or eyelids) of ocular itching associated with allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharoconjunctivitis and giant papillary conjunctivitis.
The recommended dosage of Patadin Max sterile eye drops is to instill one drop in each affected eye once a day.
*Prescription only*
Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.
Overdose:
There is no information on overdose of Olopatadine. However, excessive use of any medication can have serious consequences. If any overdose is suspected, medical attention should be sought.
There are no adequate or well-controlled studies with Olopatadine in pregnant women. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine is administered to a nursing mother.
As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. Patients should not wear a contact lens if their eye is red. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least 10 minutes after instilling Olopatadine before they insert their contact lenses. Treatment should be discontinued in the presence of an allergic reaction.
Store at below 30°C in a dry place protected from light. Do not use after one month of first opening of the bottle.